SECURITIES AND EXCHANGE COMMISSION
                                      
                           WASHINGTON, D.C.  20549
                                      
                                  FORM 8-K


                               CURRENT REPORT

                   PURSUANT TO SECTION 13 OR 15(d) OF THE
                       SECURITIES EXCHANGE ACT OF 1934
                      Date of Report:  January 22, 1998
                                      


                               MEDIMMUNE, INC.
           (Exact name of registrant as specified in its charter)



                      Commission File Number:  0-19131
                                      
                                      
                                      
                                      
          Delaware                                    52-1555759
     (State of Incorporation)                     (I.R.S. Employer
                                                  Identification No.)



     35 West Watkins Mill Road, Gaithersburg, MD      20878
     (Address of principal executive offices)       (Zip Code)


          Registrant's telephone number, including area code (301) 417-0770


                No Exhibits are being filed with this report
                                      
                                      
CytoGam and RespiGam are registered trademarks of the Company.


                               MEDIMMUNE, INC.
                         Current Report on Form 8-K


ITEM 5.  OTHER EVENTS

MedImmune, Inc. reported the information contained in the following press
release dated January 22, 1998:

              MEDIMMUNE CLOSES $66.3 MILLION PRIVATE PLACEMENT

Gaithersburg, MD, January 22, 1998 -- MedImmune, Inc. (Nasdaq:MEDI) today
announced that it has closed the private placement of 1,700,000 new shares of
common stock to institutional investors BB Biotech, Investor AB and INVESCO
Trust Company resulting in net proceeds to MedImmune of $66.3 million.  The
private placement was self-managed by MedImmune and was first announced on
January 13, 1998.  MedImmune now has 26.2 million shares outstanding.

MedImmune, Inc. is a biotechnology company focused on developing and
marketing products for the prevention and treatment of infectious diseases
and for use in transplantation medicine.  MedImmune currently markets two
products through its hospital-based sales force and has five new product
candidates in clinical trials.  MedImmune is located in Gaithersburg, MD.

This announcement may contain, in addition to historical information, certain
forward-looking statements that involve risks and uncertainties.  Such
statements reflect management's current views and are based on certain
assumptions.  Actual results could differ materially from those currently
anticipated as a result of a number of factors, including risks and
uncertainties discussed in the Company's filings with the U.S. Securities and
Exchange Commission.


(REGISTRANT)      MEDIMMUNE, INC.




BY (SIGNATURE)    /s/ David M. Mott
(NAME AND TITLE)  David M. Mott, President and Chief Operating Officer
                                (Principal financial and accounting officer)
(DATE)            January 22, 1998
[{"type": "8-K", "sequence": "1", "secsgml_size_bytes": 3235}]
{"company-data": {"conformed-name": "MEDIMMUNE INC /DE", "cik": "0000873591", "assigned-sic": "2836", "irs-number": "521555759", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-19131", "film-number": "98511112"}, "business-address": {"street1": "35 W WATKINS MILL RD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878", "phone": "3014170770"}, "mail-address": {"street1": "35 W WATKINS MILL ROAD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878"}}
SECURITIES AND EXCHANGE COMMISSION
                                      
                           WASHINGTON, D.C.  20549
                                      
                                  FORM 8-K

                               CURRENT REPORT

                   PURSUANT TO SECTION 13 OR 15(d) OF THE
                       SECURITIES EXCHANGE ACT OF 1934
                      Date of Report:  January 22, 1998
                                      

                               MEDIMMUNE, INC.
           (Exact name of registrant as specified in its charter)

                      Commission File Number:  0-19131
                                      
                                      
                                      
                                      
          Delaware                                    52-1555759
     (State of Incorporation)                     (I.R.S. Employer
                                                  Identification No.)

     35 West Watkins Mill Road, Gaithersburg, MD      20878
     (Address of principal executive offices)       (Zip Code)

          Registrant's telephone number, including area code (301) 417-0770

                No Exhibits are being filed with this report
                                      
                                      
CytoGam and RespiGam are registered trademarks of the Company.

                               MEDIMMUNE, INC.
                         Current Report on Form 8-K

ITEM 5.  OTHER EVENTS

MedImmune, Inc. reported the information contained in the following press
release dated January 22, 1998:

              MEDIMMUNE CLOSES $66.3 MILLION PRIVATE PLACEMENT

Gaithersburg, MD, January 22, 1998 -- MedImmune, Inc. (Nasdaq:MEDI) today
announced that it has closed the private placement of 1,700,000 new shares of
common stock to institutional investors BB Biotech, Investor AB and INVESCO
Trust Company resulting in net proceeds to MedImmune of $66.3 million.  The
private placement was self-managed by MedImmune and was first announced on
January 13, 1998.  MedImmune now has 26.2 million shares outstanding.

MedImmune, Inc. is a biotechnology company focused on developing and
marketing products for the prevention and treatment of infectious diseases
and for use in transplantation medicine.  MedImmune currently markets two
products through its hospital-based sales force and has five new product
candidates in clinical trials.  MedImmune is located in Gaithersburg, MD.

This announcement may contain, in addition to historical information, certain
forward-looking statements that involve risks and uncertainties.  Such
statements reflect management's current views and are based on certain
assumptions.  Actual results could differ materially from those currently
anticipated as a result of a number of factors, including risks and
uncertainties discussed in the Company's filings with the U.S. Securities and
Exchange Commission.

(REGISTRANT)      MEDIMMUNE, INC.

BY (SIGNATURE)    /s/ David M. Mott
(NAME AND TITLE)  David M. Mott, President and Chief Operating Officer
                                (Principal financial and accounting officer)
(DATE)            January 22, 1998